Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integral DiagnosticsASX:IDX +0.48%70 3-1 Month Momentum % is -10.31% as of Aug. 02, 2026. GuruFocus rates ASX:IDX with a GF Score™ of 70/100 and a GF Value™ of A$2.79 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Integral Diagnostics ranks worse than 60.09% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-02), Integral Diagnostics's 3-1 Month Momentum % is -10.31%.
The industry rank for Integral Diagnostics's 3-1 Month Momentum % or its related term are showing as below:
ASX:IDX's 3-1 Month Momentum % is ranked worse than 60.09% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -4.42
vs ASX:IDX: -10.31
Integral Diagnostics (ASX:IDX) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Integral Diagnostics 3-1 Month Momentum % Related Terms
ASX:IDX vs TMO, DHR, IDXX: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Integral Diagnostics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's 3-1 Month Momentum % falls into.
Integral Diagnostics (ASX:IDX) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics (ASX:IDX) has a 3-1 Month Momentum % of -10.31% as of Aug. 02, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Integral Diagnostics and its competitors. According to the industry distribution chart, Integral Diagnostics ranks #128 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 60.1%.
Is Integral Diagnostics' 3-1 Month Momentum % too high?
Integral Diagnostics' current 3-1 Month Momentum % is -10.31%. Based on the distribution chart, Integral Diagnostics ranks #128 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Integral Diagnostics has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' 3-1 Month Momentum % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #128 out of 213 companies for 3-1 Month Momentum %. This places Integral Diagnostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 3-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Integral Diagnostics and its competitors. Integral Diagnostics's current 3-1 Month Momentum % is -10.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.79, compared to a current price of A$2.10 — trading 24.7% below its estimated fair value. The current 3-1 Month Momentum % is -10.31%. Integral Diagnostics' overall GF Score™ is 70/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current 3-1 Month Momentum % is -10.31% as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued.
The current stock price of A$2.10 is trading 24.7% below its estimated GF Value™ of A$2.79.
GuruFocus considers Integral Diagnostics to be Modestly Undervalued.
Key valuation signals for ASX:IDX:
3-1 Month Momentum %: -10.31%
GF Value™: A$2.79 vs. price of A$2.10 (24.7% below fair value)
No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
70GF Score
Get the complete analysis for ASX:IDX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDX has been successfully added to your 
